Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B

BRISTOL MYERS SQUIBB CO

2025-Q3 EPS reported $2.93 revenue$35,692,000,000

Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).
GAAP EPS $1.08 (up 81% YoY); non-GAAP EPS $1.63 (down 9% YoY); both include $(0.20) net impact from Acquired IPRD and licensing.
FY 2025 revenue guidance raised to ~$47.5B-$48.0B; non-GAAP EPS expected $6.40-$6.60 (includes $(0.80) net Acquired IPRD impact).
Q3 2024 comparatives: revenue $11,892M, GAAP EPS $0.60, non-GAAP EPS $1.80.
CEO cites Growth Portfolio momentum, pipeline advancements, and strategic business development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.